WRF Capital

Proniras Corporation is a preclinical-stage biotechnology company based in Seattle, Washington, focused on developing innovative parenteral medical countermeasure drugs, particularly tezampanel, for treating seizures and brain injuries. Founded in 2016, the company has demonstrated preclinical efficacy in addressing nerve agent-induced seizures, particularly in studies involving exposure to soman, a highly toxic chemical weapon. By targeting the central nervous system, Proniras aims to develop novel small-molecule therapeutics for various neurological conditions characterized by high unmet medical needs. Their research is designed to provide medical researchers with valuable tools for advancing treatments in this critical area.

AdaptX is a Seattle-based healthcare technology company established in 2016, spun out from Seattle Children's Hospital. It specializes in data analytics, visualization, and AI for hospitals and surgery centers. The company's core product is a clinical healthcare analytics platform that integrates with institutions' existing electronic data systems. This platform enables medical professionals to monitor, analyze, and improve clinical outcomes and workflows, ultimately enhancing care quality and reducing costs. AdaptX empowers both medical leaders and frontline clinicians to make data-driven decisions, transforming clinical operations within healthcare providers' facilities.

Somalytics is a Seattle-based company that specializes in the development and commercialization of innovative miniature sensors for applications such as eye tracking, human-machine interfaces, wearables, and industrial safety. Founded in 2021, the company has created the world's first paper-composite capacitive sensor, which is ultra-thin, energy-efficient, and potentially disposable. These carbon nanotube-based sensors enhance sensitivity and aim to replace traditional cameras and sensors in various devices, thereby improving the overall human experience through advanced technology.

AdaptX is a Seattle-based healthcare technology company established in 2016, spun out from Seattle Children's Hospital. It specializes in data analytics, visualization, and AI for hospitals and surgery centers. The company's core product is a clinical healthcare analytics platform that integrates with institutions' existing electronic data systems. This platform enables medical professionals to monitor, analyze, and improve clinical outcomes and workflows, ultimately enhancing care quality and reducing costs. AdaptX empowers both medical leaders and frontline clinicians to make data-driven decisions, transforming clinical operations within healthcare providers' facilities.

2Morrow is a digital health company that develops, licenses, and distributes evidence-based behavioral change programs and digital health products. Its programs include SmartQuit, an evidence-based smoking cessation program using acceptance commitment therapy; My Pocket Coach, a personal goal and habit platform; and Healthy Habits to establish or break routines. Delivered through employers, state programs, wellness initiatives, and health plans, the offerings support population health and well-being. The company emphasizes behavioral science and data-driven tools, with more than a dozen published studies and a Phase III randomized controlled trial in digital health. Based in Kirkland, Washington, 2Morrow has an active product pipeline extending into substance-use support and management of chronic conditions, helping individuals align behavior with personal values to sustain lasting change.

ThruWave develops millimeter wave imaging technology for various industries. Founded in 2017, it's headquartered in Seattle, Washington.

WiBotic Inc. is a company specializing in wireless charging and power optimization solutions for robotic systems, including aerial, mobile, and underwater vehicles. Established in 2014 and headquartered in Seattle, Washington, WiBotic develops a range of products, including wireless charging systems, transmitters, onboard chargers, and antenna coils, as well as professional services. The company also offers advanced power management software that enhances battery performance and optimizes the operational efficiency of entire fleets of robots. This technology automatically detects when a robot or drone approaches a charging platform, facilitating seamless and autonomous battery charging. WiBotic's solutions are designed to be safe, reliable, and scalable, enabling clients to reduce charging and maintenance costs while maximizing battery lifespan and operational capabilities.

Founded in 2016, Membrion specializes in manufacturing and commercializing advanced membrane filtration technologies. Its products are designed to filter molecules under diverse conditions, serving applications such as flow batteries, water purification, fuel cells, and pharmaceuticals.

AnswerDash, Inc. is a technology company that specializes in providing contextual answer services for websites and mobile applications. Founded in 2012 and based in Seattle, Washington, AnswerDash offers a cloud-based platform that allows businesses to deliver self-service, point-and-click answers to users, thereby improving customer experience and reducing support costs. The platform integrates seamlessly with existing live chat services, enabling customers to seek personalized assistance when needed. By predicting user questions based on web page content and employing artificial intelligence, AnswerDash ensures that relevant information is readily available at the point of action. The company was previously known as Qazzow, Inc. until its name change in May 2014 and currently operates as a subsidiary of CloudEngage, Inc.

FlexMinder, Inc. is a Seattle-based company that specializes in developing enterprise software solutions for private health exchanges, health carriers, and third-party administrators. Founded in 2011, FlexMinder focuses on automating the healthcare reimbursement process, specifically for flexible spending accounts. The company's software aggregates healthcare information from various sources, streamlining the claims submission process for participants and significantly reducing manual processing time and costs for third-party administrators. By offering online tools that enhance the management of healthcare reimbursement accounts, FlexMinder aims to improve user experience and facilitate better financial management in the healthcare sector. As of January 2017, FlexMinder operates as a subsidiary of Jelleyvision Lab Inc.

SNUPI Technologies, Inc. is a Seattle-based company specializing in sensor technology and services aimed at enhancing home safety, security, and loss prevention. Founded in 2012, the company has developed a wireless sensing platform that utilizes existing electrical wiring within homes to facilitate communication. Its flagship product, WallyHome, is designed to monitor environmental conditions such as moisture, temperature, and humidity, providing homeowners with alerts about potential hazards like water leaks and mold growth. SNUPI Technologies focuses on protecting homes from various dangers, including water, smoke, heat, and methane, through its innovative sensing solutions. As of October 2015, it operates as a subsidiary of Sears Holdings Corporation.

Mobisante, Inc. is a Redmond, Washington-based company that specializes in the development of cellphone-based diagnostic devices, particularly focusing on ultrasound technology. Founded in 2009, Mobisante aims to enhance medical imaging by providing safe, simple, non-invasive, and affordable ultrasound solutions that can be utilized by emergency physicians, surgeons, academic medical centers, and community clinics. Their products enable clinicians to conduct imaging closer to the point of patient care, which has been shown to improve clinical outcomes and healthcare efficiency. By leveraging advanced mobile computing technology, Mobisante offers more accessible and cost-effective imaging alternatives compared to traditional, complex systems. In addition to human healthcare, the company is expanding its offerings to veterinarians in the United States, providing portable imaging solutions for companion animal diagnosis and treatment.

Modumetal, Inc. specializes in the development and manufacturing of nano-laminated metals and materials, catering to various industries including energy, aerospace, automotive, defense, infrastructure, and construction. Founded in 2006 and based in Seattle, Washington, with an additional sales office in The Woodlands, Texas, the company utilizes a proprietary technology that produces these alloys at an industrial scale. Modumetal's products are engineered to be stronger, lighter, and more corrosion-resistant than traditional metals, achieved through a manufacturing process that employs electricity instead of heat, thereby minimizing environmental impact. The company's offerings include customized alloys, nano-laminated fasteners, pumps, valves, and production tubulars, all designed to enhance performance and durability while maintaining competitive pricing compared to conventional materials.

GlobeImmune, Inc. is a biopharmaceutical company based in Louisville, Colorado, specializing in the development of therapeutic products for cancer and infectious diseases utilizing its proprietary Tarmogen platform. Founded in 1995 as Ceres Pharmaceuticals, the company focuses on creating targeted molecular immunotherapies. Its product pipeline includes GS-4774, currently in Phase 2 trials for chronic hepatitis B infection, and GI-6301, aimed at cancers expressing the brachyury protein. Additionally, GlobeImmune is advancing GI-6207 for medullary thyroid cancer and GI-4000 for resected pancreatic cancer, with multiple Phase 2 clinical trials for various other cancers, including non-small cell lung cancer and colorectal cancer. The company is also developing several candidates targeting infectious diseases, including GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D, which are in preclinical stages. GlobeImmune has established strategic collaborations with notable organizations, enhancing its research and development efforts.

Omeros discovers, develops, and commercializes small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system, immunologic disorders, cancers, and addictive/compulsive disorders.

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Bothell, Washington, focused on discovering, developing, and commercializing therapeutic antibodies. The company aims to transform treatment paradigms for patients with migraine and other conditions, utilizing proprietary technologies to enhance the efficacy and durability of therapeutic responses. Its lead product candidate, eptinezumab, is a monoclonal antibody designed to prevent migraines, currently in late-stage clinical development. Additionally, Alder is developing ALD1910, a preclinical monoclonal antibody for migraine prevention, and Clazakizumab, which targets interleukin-6 and has completed two Phase 2b clinical trials. Alder also collaborates with CSL Limited to develop Clazakizumab for preventing solid organ transplant rejection. The company operates primarily in the United States, Australia, and Ireland, where it seeks to address unmet medical needs in various therapeutic areas, including cancer, autoimmune diseases, and inflammatory disorders. Founded in 2002, Alder BioPharmaceuticals operates as a subsidiary of H. Lundbeck A/S.